Plain-English translation of NCT07507201 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing QT-219C, a new type of cell therapy made from immune cells donated by healthy people. The medication is engineered to target and remove specific immune cells that cause autoimmune diseases. The study will evaluate whether this treatment is safe and whether it helps patients whose autoimmune conditions haven't responded to standard medications.
Many patients with serious autoimmune diseases like lupus, vasculitis, or kidney disease do not improve with standard treatments and face severe side effects. This medication represents a new approach — instead of just suppressing the immune system, it aims to reset it by removing the specific harmful immune cells that drive these diseases.
You likely qualify if…
You likely don't qualify if…
You will receive a mild chemotherapy treatment to prepare your body, followed by a single intravenous infusion of the new immune cells. The study starts with small groups of patients to test safety before gradually increasing doses. You will have regular blood tests and clinic visits to monitor how the medication is working and to watch for side effects. The trial is still in early stages, so the exact duration and number of visits will depend on your specific disease and how you respond.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China